62,734
edits
Changes
no edit summary
|-
| 2016 (December) || || || Study || A study finds the {{w|rVSV-ZEBOV vaccine}} against {{w|Ebola virus disease}} to be 95-100% effective, making it the first proven vaccine against the disease.<ref name="TL-20161222">{{cite journal |vauthors=Henao-Restrepo AM, Camacho A, Longini IM, Watson CH, Edmunds WJ, Egger M, Carroll MW, Dean NE, Diatta I, Doumbia M, Draguez B, Duraffour S, Enwere G, Grais R, Gunther S, Gsell PS, Hossmann S, Watle SV, Kondé MK, Kéïta S, Kone S, Kuisma E, Levine MM, Mandal S, Mauget T, Norheim G, Riveros X, Soumah A, Trelle S, Vicari AS, Røttingen JA, Kieny MP|display-authors=6 |title=Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ça Suffit!) |journal = Lancet |volume = 389 |issue = 10068 |pages = 505–518 |year = 2017 |pmid = 28017403 |pmc = 5364328 |doi = 10.1016/S0140-6736(16)32621-6 }}</ref><ref name="CNN-2016122">{{cite news |last=Berlinger |first=Joshua |title=Ebola vaccine gives 100% protection, study finds |url=http://www.cnn.com/2016/12/22/health/ebola-vaccine-study/index.html |date=22 December 2016 |work=[[CNN]] |accessdate=25 April 2018}}</ref> ||
|-
| 2017 || August 25 || {{w|Influenza}} || Recommendation || "CDC published ACIP 2017–18 influenza vaccination recommendations."<ref>{{cite web |last1=Grohskopf |first1=Lisa A. |last2=Sokolow |first2=Leslie Z. |last3=Broder |first3=Karen R. |last4=Walter |first4=Emmanuel B. |last5=Bresee |first5=Joseph S. |last6=Fry |first6=Alicia M. |last7=Jernigan |first7=Daniel B. |title=Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices — United States, 2017–18 Influenza Season |url=https://www.cdc.gov/mmwr/volumes/66/rr/rr6602a1.htm |website=cdc.gov |accessdate=2 June 2020}}</ref> ||
|-
| 2017 || August 31 || {{w|Influenza}} || Vaccine approval || "FDA expanded licensure of Afluria quadrivalent (Seqirus) to include people age 5 years and older."<ref>{{cite web |title=BLA Clinical Review Memorandum |url=https://www.fda.gov/media/107499/download |website=fda.gov |accessdate=2 June 2020}}</ref> ||
